BMRA
Biomerica, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.42
P/S
1.47
EV/EBITDA
-1.17
DCF Value
$-80.65
FCF Yield
-44.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
5.6%
Operating Margin
-118.1%
Net Margin
-90.3%
ROE
-83.7%
ROA
-69.2%
ROIC
-111.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $1.2M | $-1.3M | $-0.45 |
| Q1 2026 | $1.4M | $2.0K | $0.00 |
| Q4 2025 | $749.0K | $-1.5M | $-0.16 |
| FY 2025 | $5.3M | $-5.0M | $-2.16 |
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.20
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.